Clinical trials: Thyroid Cancers
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Differentiated Thyroid Cancer, Advanced Cancer
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC).
- Trial name
- NCT04321954
- Testing
- LENVATINIB
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Differentiated Thyroid Cancer
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with Donafenib 0.3g Bid by continuous oral…
- Trial name
- DTC (NCT03602495)
- Testing
- Donafenib
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Differentiated Thyroid Cancer
A Prospective Study to Collect Images in Patients Treated With Iodine-131 as Part of a European Research Project in Radiation Protection.
This trial is a prospective, non-interventional, monocentric study aiming to collect standard of care imaging of patients treated with Iodine-131 for the determination of dosimetric studies.
- Trial name
- MEDIRAD (NCT03986437)
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Institut Claudius Regaud
Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
This clinical trial evaluates the impact of a patient-centered health and wellness coaching (HWC) intervention on adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid…
- Trial name
- NCT07545837
- Testing
- Counseling, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Thyroid Cancer, Papillary, Primary Aldosteronism
Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer
Aldosterone excess can cause oxidative stress leading to DNA damage in vitro and in vivo. Single case reports demonstrated a coincidence of primary aldosteronism (PA) with different malignancies.
- Trial name
- NCT06068101
- Testing
- Secreening test for primary aldosteronism and Confirmatory Testing
- Where
- Brazil
- Volunteers
- 274 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Thyroid Cancer
Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer
The effect of iodine nutritional status on thyroid cancer has been controversial for many years. We designed a prospective cohort study that recruiting patients in different iodine areas who underwent thyroid cancer surgery in…
- Trial name
- NCT06623500
- Testing
- Iodine excess, Iodine suitable
- Where
- China
- Volunteers
- 1,600 people
- Sponsor
- Shandong Provincial Hospital
Hypothyroidism, Brain Tumor
Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors
Primary Objectives: 1. Assess whether combined treatment with Levothyroxine and Liothyronine improves learning and memory. 2. Explore the relationship between T3 treatment and other domains of cognitive function, quality of life…
- Trial name
- NCT00488644
- Testing
- Levothyroxine, Liothyronine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Carcinoma
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
The objective of this study is to determine the feasibility of pazopanib treatment interruption with reintroduction at progression in iodine refractory progressive Differentiated Thyroid Cancer (DTC) patients as compared to…
- Trial name
- NCT01813136
- Testing
- Continuous pazopanib (Arm A), Intermittent pazopanib (Arm B)
- Where
- 13 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Papillary Thyroid Carcinoma, Lymph Node Cancer Metastatic
Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma
Establish a predictive model for assessing neck lymph node metastasis of papillary thyroid carcinoma based on metabolomics, proteomics, and imaging omics data, exploring an ideal protocal for the precise diagnosis and treatment…
- Trial name
- NCT06725628
- Testing
- Thy_CLNM_multi_omics
- Volunteers
- 2,000 people
- Sponsor
- Tianhan Zhou
Thyroid Cancer
Adjuvant Radiotherapy in High Risk Locally Advanced DTC
This study is a phase III randomized controlled clinical trial on the role of adjuvant radiotherapy in high-risk locally advanced differentiated thyroid cancer.
- Trial name
- NCT06558981
- Testing
- Radiotherapy, radioiodine treatment
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Fudan University
Solid Tumors, Thyroid Cancer
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
- Conditions
- Solid Tumors, Thyroid Cancer, Soft-tissue Sarcoma, Cholangiocarcinoma
- Trial name
- NCT01438554
- Testing
- Pazopanib, GSK1120212
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Tumor and Hematologic Malignancies
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT01885195)
- Testing
- MEK162
- Where
- 68 sites in United States
- Volunteers
- 110 people
- Sponsor
- Pfizer
Non-Medullary Thyroid Carcinoma
Digoxin for the Reinduction of Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Carcinoma
Non-medullary thyroid carcinoma has a good prognosis in most patients. However, a small subset of patients nevertheless develop metastatic or locally advanced and unresectable disease which in some cases also becomes radioiodine…
- Trial name
- DIGUP-TC (NCT05507775)
- Testing
- Digoxin tablet
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Radboud University Medical Center
Thyroid Nodule
The Diagnostic Value of Shear Wave Elastography
Background: The main goal when diagnosing thyroid nodules, is to differentiate the few malignant from the overwhelming background of benign nodules.
- Trial name
- NCT02150772
- Testing
- Shear Wave Elastography (SWE)
- Where
- Denmark
- Volunteers
- 308 people
- Sponsor
- University of Aarhus
Type 2 Diabetes, Thyroid Cancer
Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer
Persistent organic pollutants (POPs) are a class of organic pollutants in the environment characterized by persistent, bioaccumulation, long-range transport and biological toxicity.
- Conditions
- Type 2 Diabetes, Thyroid Cancer, Organic Pollutant
- Trial name
- NCT05218395
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging.
- Conditions
- Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06141369
- Testing
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.